Literature DB >> 14619251

Should commercial-in-confidence data be used by decision makers when making assessments of cost-effectiveness?

Michael Drummond1.   

Abstract

Mesh：

Year:  2002        PMID： 14619251

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN： 1175-5652            Impact factor:   2.561


× No keyword cloud information.
  2 in total

Review 1.  Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle.

Authors:  R S Taylor; M F Drummond; G Salkeld; S D Sullivan
Journal:  BMJ       Date:  2004-10-23

Review 2.  Moving from opacity to transparency in pharmaceutical policy.

Authors:  Irfan Dhalla; Andreas Laupacis
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.